[Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections].
Kagaya
Hidetoshi
H
Department of Internal Medicine, Keiyukai Sappolo Hospital.
Kato
Mototsugu
M
Asaka
Masahiro
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000658:Amoxicillin / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000494:pharmacology; D017291:Clarithromycin; D002986:Clinical Trials as Topic; D004224:Diterpenes / Q000008:administration & dosage* / Q000494:pharmacology; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; C061681:ecabet; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole